Activation of the plasma kallikrein/kinin system on endothelial cell membranes.

For more than three decades, it has been known that the plasma kallikrein/kinin system becomes activated when exposed to artificial, negatively charged surfaces. The existence of an encompassing in vivo, negatively charged surface capable of activation of the plasma kallikrein/kinin system has, however, never been convincingly demonstrated. In this report, we describe current knowledge on how the proteins of the plasma kallikrein/kinin system assemble to become activated on cell membranes. On endothelial cells, the activation of the plasma kallikrein/kinin system is not initiated by factor XII autoactivation as seen on artificial surfaces. On endothelial cells, prekallikrein is activated by an antipain sensitive protease. Prekallikrein activation is dependent on the presence of high molecular weight kininogen and an optimal free Zn2+ concentration. Kallikrein generated on the surface of endothelial cell is capable of activating factor XII. Further, kallikrein formed on endothelial cell membranes is capable of cleaving its receptor and native substrate, high molecular weight kininogen, liberating bradykinin and the HK PK complex from the endothelial cell surface. Endothelial cell-associated kallikrein also is capable of kinetically favorable pro-urokinase and, subsequent, plasminogen activation.

[1]  M. Johnstone,et al.  Platelet-Bound Prekallikrein Promotes Pro-Urokinase-Induced Clot Lysis: A Mechanism for Targeting the Factor XII Dependent Intrinsic Pathway of Fibrinolysis , 1994, Thrombosis and Haemostasis.

[2]  R. Mandle,et al.  An HMG-I protein from human endothelial cells apparently is secreted and impairs activation of Hageman factor (factor XII). , 1998, Proceedings of the Association of American Physicians.

[3]  M. Silverberg,et al.  Autoactivatability of human Hageman factor (factor XII). , 1980, Biochemical and biophysical research communications.

[4]  A. Prasad,et al.  Zinc in plasma, neutrophils, lymphocytes, and erythrocytes as determined by flameless atomic absorption spectrophotometry. , 1982, Clinical chemistry.

[5]  D. Vaughan,et al.  Selective Stimulation of Tissue-Type Plasminogen Activator (t-PA) In Vivo by Infusion of Bradykinin , 1997, Thrombosis and Haemostasis.

[6]  R. Gorodetsky,et al.  Packaging zinc, fibrinogen, and factor XIII in platelet α‐granules , 1993 .

[7]  J. Henkin,et al.  Enhancement of the Enzymatic Activity of Single-chain Urokinase Plasminogen Activator by Soluble Urokinase Receptor (*) , 1995, The Journal of Biological Chemistry.

[8]  A. Schmaier,et al.  The expression of high molecular weight kininogen on human umbilical vein endothelial cells. , 1988, The Journal of biological chemistry.

[9]  V. Gurewich,et al.  Pro‐urokinase and prekallikrein are both associated with platelets , 1993, FEBS letters.

[10]  M. Rocha e Silva,et al.  Bradykinin, a hypotensive and smooth muscle stimulating factor released from plasma globulin by snake venoms and by trypsin. , 1949, The American journal of physiology.

[11]  R. Colman,et al.  The sequence HGLGHGHEQQHGLGHGH in the light chain of high molecular weight kininogen serves as a primary structural feature for zinc‐dependent binding to an anionic surface , 1992, Protein science : a publication of the Protein Society.

[12]  H. Saito.  Contact Factors in Health and Disease , 1987, Seminars in thrombosis and hemostasis.

[13]  N. Ziats,et al.  Inhibition of the activation of Hageman factor (factor XII) by human vascular endothelial cell culture supernates. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[14]  E. Peerschke,et al.  Identification of the zinc-dependent endothelial cell binding protein for high molecular weight kininogen and factor XII: identity with the receptor that binds to the globular "heads" of C1q (gC1q-R). , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[15]  J. Dunn,et al.  Autoactivation of human Hageman factor. Demonstration utilizing a synthetic substrate. , 1980, The Journal of biological chemistry.

[16]  A. Schmaier,et al.  Factor XII Does not Initiate Prekallikrein Activation on Endothelial Cells , 1998, Thrombosis and Haemostasis.

[17]  A. Retzios,et al.  Effects of chemical modifications on the surface- and protein-binding properties of the light chain of human high molecular weight kininogen. , 1987, The Journal of biological chemistry.

[18]  C. Cochrane,et al.  The autoactivation of rabbit hageman factor , 1979, The Journal of experimental medicine.

[19]  S. Reddigari,et al.  Human Hageman factor (factor XII) and high molecular weight kininogen compete for the same binding site on human umbilical vein endothelial cells. , 1993, The Journal of biological chemistry.

[20]  V. Donaldson,et al.  Endothelial cells produce a substance that inhibits contact activation of coagulation by blocking the activation of Hageman factor. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[21]  A. Schmaier,et al.  Contact system: a vascular biology modulator with anticoagulant, profibrinolytic, antiadhesive, and proinflammatory attributes. , 1997, Blood.

[22]  M. Gilbert,et al.  Tissue plasminogen activator release in vivo in response to vasoactive agents. , 1985 .

[23]  V. Gurewich,et al.  Assembly and Activation of the Intrinsic Fibrinolytic Pathway on the Surface of Human Endothelial Cells in Culture , 1995, Thrombosis and Haemostasis.

[24]  K. Fujikawa,et al.  The activation of pro-urokinase by plasma kallikrein and its inactivation by thrombin. , 1986, The Journal of biological chemistry.

[25]  I. Schousboe,et al.  Partial identification of the Zn2+-binding sites in factor XII and its activation derivatives. , 1997, European journal of biochemistry.

[26]  S. Iwanaga,et al.  Accelerating effect of zinc ions on the surface-mediated activation of factor XII and prekallikrein. , 1987, Journal of biochemistry.

[27]  E. Davie,et al.  Waterfall Sequence for Intrinsic Blood Clotting , 1964, Science.

[28]  I. Schousboe,et al.  The surface-dependent autoactivation mechanism of factor XII. , 1997, European journal of biochemistry.

[29]  A. Schmaier,et al.  Bradykinin regulates the expression of kininogen binding sites on endothelial cells. , 1993, Blood.

[30]  R. Gorodetsky,et al.  Platelet multielemental composition, lability, and subcellular localization , 1993, American journal of hematology.

[31]  A. Schmaier,et al.  Low molecular weight kininogen binds to platelets to modulate thrombin-induced platelet activation. , 1991, The Journal of biological chemistry.

[32]  J. Griffin,et al.  A comparison of the abilities of plasma kallikrein, beta-Factor XIIa, Factor XIa and urokinase to activate plasminogen. , 1983, Thrombosis research.

[33]  R. Schein,et al.  Structural changes of plasma high molecular weight kininogen after in vitro activation and in sepsis. , 1988, The Journal of laboratory and clinical medicine.

[34]  A. Schmaier,et al.  High molecular weight kininogen binds to platelets by its heavy and light chains and when bound has altered susceptibility to kallikrein cleavage. , 1992, Blood.

[35]  A. Schmaier,et al.  High molecular weight kininogen regulates prekallikrein assembly and activation on endothelial cells: a novel mechanism for contact activation. , 1998, Blood.

[36]  H. Büller,et al.  Reduction of contact activation related fibrinolytic activity in factor XII deficient patients. Further evidence for the role of the contact system in fibrinolysis in vivo. , 1991, The Journal of clinical investigation.

[37]  P. D. de Groot,et al.  The binding of high molecular weight kininogen to cultured human endothelial cells. , 1988, The Journal of biological chemistry.

[38]  A. Schmaier,et al.  Activation of the plasma kallikrein/kinin system on endothelial cells. , 1999, Proceedings of the Association of American Physicians.